FDA’s new mammography proposal to help enhance diagnosis accuracy
Category: #health  By Mateen Dalal  Date: 2019-03-29
  • share
  • Twitter
  • Facebook
  • LinkedIn

FDA’s new mammography proposal to help enhance diagnosis accuracy

The FDA (Food & Drug Administration) has reportedly proposed a new rule that would require mammography providers to inform female patients with dense breast tissue about the fact that the condition may impact the accuracy of their mammograms. The proposed regulation, apparently, will help women ponder over whether they need to consult their doctors regarding additional tests for checking on breast cancer.

The issue has turned out to be immensely critical in the wake of recent findings highlighting that dense breast tissue is a major cause behind the incline in the chances of breast cancer development. Sources with the knowledge of the matter revealed that the growth of the dense breast tissue makes it quite difficult to discover malignancies on the mammograms. Reports state that around three dozen states already have several laws concerning breast density notifications, however, FDA’s latest proposal aims to establish a standard that is applicable throughout the nation. 

The proposal is expected to upgrade the regulations mentioned under the Mammography Quality Standards Act, 1992, which helped bring around 8,000 mammography facilities in the United States under federal supervision. The rules, for the record, involve annual inspections, authorization of the facilities and enforcement of effective mammography rules.

According to The Washington Post, the NCI (National Cancer Institute) has reported that dense breasts contain rather high amounts of fibrous connective tissue and glandular tissue, while having low amount of fatty tissue. Nowadays, women at the age of 40 and older get diagnosed with dense breasts through their mammograms, and since such tissue seems white on the mammogram, resembling cancer, it tends to cover the malignancies. However, the dense breasts enhance the risk of developing breast cancer, confirmed the NCI.

Reportedly, the latest proposal is likely to incorporate advances including 3-D digital screening tools, into mammography services. It would help the agency notify patients, along with their healthcare providers, if a mammography provider fails to meet the quality standard and the need for a repeat test arises.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Mercedes-AMG Petronas F1 Team and AMD team-up for F1 2020
Mercedes-AMG Petronas F1 Team and AMD team-up for F1 2020
By Mateen Dalal

Mercedes-AMG Petronas F1 Team, and Advanced Micro Devices (AMD), a renowned semiconductor developer, have reportedly announced a new multi-year partnership agreement that has combined the two firms’ passion of for high performance, beginning fr...

Aduro begins trial of MK-5890 for non-small cell lung cancer treatment
Aduro begins trial of MK-5890 for non-small cell lung cancer treatment
By Mateen Dalal

The biopharmaceutical giant has also received a USD 10 million development milestone payment from Merck & CO. for the initiation of the trial A clinical-stage biopharmaceutical company, Aduro Biotech, Inc. recently announced to have ba...

TherapeuticsMD submits a New Drug Application to the FDA for BIJUVA®
TherapeuticsMD submits a New Drug Application to the FDA for BIJUVA®
By Mateen Dalal

TherapeuticsMD, Inc., an inventive pharmaceutical company that focuses on women healthcare, has recently announced that it has presented a New Drug Application (NDA) pre-approval efficacy supplement to the U.S. FDA (Food and Drug Administration) for ...